Intelsat Announces Planned Retirement of Stephen Spengler as Chief Executive Officer
Intelsat S.A. (OTC: INTEQ), operator of the world’s largest and most advanced integrated satellite and terrestrial network, announced today that Chief Executive Officer Stephen Spengler has decided to retire as CEO upon the Company’s emergence from its financial restructuring process and the naming of a successor. Until that time, Spengler will continue as CEO and lead Intelsat through the final stages of this process, ensuring a smooth transition.
“We are nearing the conclusion of our restructuring with enhanced financial strength and are ideally positioned to embark on an exciting new business strategy for the next generation of 5G network connectivity,” Spengler said. “This is the right moment to make my retirement plans clear so that work can begin on identifying a new leader for the long term.”
Dave McGlade, Chairman of the Board, said, “Steve has served Intelsat for more than 18 years in various senior leadership capacities and as CEO for the last six and a half years. His deep understanding of our customers’ needs resulted in many years of commercial success. His steadfast stewardship of the Company as we undertook our financial restructuring has also been commendable. He has helped build the foundation for a strong future, and we are grateful.”
Egon Zehnder, a leading executive search firm, has been engaged to lead the search process for a new CEO.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses, and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005609/en/
Contact information
Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 10:00:00 EET | Press release
AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in AI-specific security tools, either with new or existing budgets, according to the 2025 Thales Data Threat Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211710650/en/ Thales AI Security Fabric Thales is introducing the first foundational capabilities of its AI Security Fabric to protect the core and edge of enterprises' AI ecosystems. Thales AI Security Fabric – Safeguarding LLM-Powered Apps, Data, and Identities With Thales AI Security Fabric, organizations will be able to: Unlock AI-driven growth securely: Maximize AI’
Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 10:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 09:30:00 EET | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick to gain greater insights and understanding of the Japanese company, as the first non-Japanese CEO in the company’s long history. By reverting to the single leader model under Mullick in 2026, Kyowa Kirin aims
Tosi solmi merkittävän sopimuksen johtavan midstream-yhtiön EPIC Cruden kanssa11.12.2025 09:07:00 EET | Tiedote
OT-kyberturvallisuusalustojen globaali johtaja Tosi vahvistaa toimintaansa Yhdysvalloissa, ja yhtiö on solminut merkittävän tilaussopimuksen raakaöljyn kuljetuspalveluja tarjoavan johtavan midstream-toimijan EPIC Cruden kanssa. Aiemmin tänä vuonna solmittu arvoltaan kuusinumeroinen tilaussopimus on Tosin historian suurin. Sopimus vahvistaa merkittävästi Tosin asemaa öljy- ja kaasuteollisuudessa. Sopimus kattaa OT-verkkoinfrastruktuurin kokonaisvaltaisen korvaamisen uudella ratkaisulla sekä jatkuvan ylläpidon EPIC Cruden laaja-alaisissa toiminnoissa. EPIC Crudella on eri puolilla Texasia putkistoa 800 mailin pituudelta yhdistäen Delawaren, Midlandin ja Eagle Fordin öljykentät Meksikonlahden markkinoihin. EPIC Crude valitsi liiketoimintansa muuttuessa Tosin toimittamaan nopean, skaalautuvan ja kustannustehokkaan ratkaisun yhtiön nykyisen kuitupohjaisen verkon tilalle. Ennen käyttöönottoa Tosin tiimi perehtyi konsultoivalla lähestymistavalla EPIC Cruden liiketoimintavaatimuksiin. Tältä po
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin11.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210261871/en/ CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause.1 It is a common condition and prevalent in nearly 30% of the elderly in certain populations, but despite its debilitating impact – with effects on sleep, mental health, and overall quality of life – there are currently no approved treatments.1,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom